On Tuesday, the S&P/ASX 200 Index (ASX: XJO) ended the day in the red. The benchmark index fell 0.3% to 8,816.9 points
Will the market be able to bounce back from this on Wednesday? Here are five things to watch:
ASX 200 to rebound
The Australian share market is expected to rise on Wednesday following a mixed session on Wall Street. According to the latest SPI futures, the ASX 200 is expected to open the day 32 points or 0.35% higher. In the United States, the Dow Jones rose 1% and the S&P 500 climbed 0.3%, but the Nasdaq was down a fraction.
Oil prices fall
ASX 200 energy shares Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a poor session after oil prices fell overnight. According to Bloomberg, the WTI crude oil price is down 2.5% to US$101.09 a barrel and the Brent crude oil price is down 0.5% to US$108.97 a barrel. Traders were selling oil amid optimism over diplomatic progress in the Middle East.
Sigma update
Sigma Healthcare Ltd (ASX: SIG) shares will be on watch on Wednesday when the Chemist Warehouse owner releases a trading update at its annual general meeting. Bell Potter is expecting the company to reveal that it started the financial year strongly. It said: "We expect 1Q27 network LFL network sales growth in the range of 12-13%."
Gold price falls
ASX 200 gold shares including Westgold Resources Ltd (ASX: WGX) and Northern Star Resources Ltd (ASX: NST) could have a subdued session after the gold price fell overnight. According to CNBC, the gold futures price is down 0.45% to US$4,141.3 an ounce. Traders were selling gold in response to rate hike fears.
Buy Pro Medicus shares
Pro Medicus Ltd (ASX: PME) shares could be a top pick for Aussie investors according to Morgans. It has upgraded the health imaging technology company's shares to a buy rating with a $230.00 price target. It said: "PME has announced a further seven-year, A$24m full stack cloud contract with Billings Clinic Logan Health, its third new community health system win in FY27 to date (A$72m TCV, A$10.3m new ARR). The FY27 wins are modest individually but consistent in size, term and scope, pointing to a repeatable mid-market playbook that broadens the pipeline beyond large Integrated Delivery Networks. Near-term focus shifts to RSNA in late November as the likely window for a larger deal, and to execution on a busy 1Q'CY27 go-live schedule underpinning FY28. We upgrade to a BUY (from Accumulate), with no change to our A$230 target price."
The post 5 things to watch on the ASX 200 on Wednesday appeared first on The Motley Fool Australia.
Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026